Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abilify approved for bipolar adolescents

Executive Summary

Bristol-Myers Squibb and Otsuka Pharmaceutical's Abilify (aripiprazole) wins approval for the acute treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features, in patients 10 to 17 years old, the firms announce Feb. 29. The approval provides clinicians with expanded treatment options for pediatric patients with bipolar I disorder, following approval in August for Johnson & Johnson's Risperdal (risperidone) for that age group. Last November, Bristol/Otsuka's dopamine partial agonist, which was already indicated for treatment of bipolar I disorder and schizophrenia, won approval for treatment of schizophrenia in adolescents (1"The Pink Sheet" Feb. 4, 2008, p. 10)
Advertisement

Related Content

Bristol Readies Abilify Sales Force For Major Depressive Disorder Push
Bristol Readies Abilify Sales Force For Major Depressive Disorder Push
Advertisement
UsernamePublicRestriction

Register

PS049347

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel